Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Schools to start reopening after Nigeria mass abduction - 2Syrian army says recent drone attacks targeted its bases near Iraq, most shot down
- 3South Korea launches Earth-observation satellite on homegrown Nuri rocket
- 4Pulsars to the extreme: Spinning dead stars found blasting radio signals from the 'edge of their magnetic reach'
- 5Sea Ice Hits New Low in Hottest Year on Record for the Arctic
- An eye for an eye: People agree about the values of body parts across cultures and eras
- America's Confided in Cooler in 2024
- NASA Artemis II tracker: Where is the Orion now and when will it reach the moon?
- The most effective method to Settle on Informed Conclusions about Senior Insuranc.
- What Yogurt Types Do You Know
- Remains of banker missing since 1999 found on California beach by family looking for seashells
- Without evidence, CDC changes messaging on vaccines and autism
- Yoshi mania, Happy Meals and not-so-great reviews: A small talk guide to 'The Super Mario Galaxy Movie'
- 5 Food varieties to Remember for Your Eating regimen for Ideal Wellbeing
